Vericel (VCEL) Announces Publication of Ixmyelocel-T Phase 2b ixCELL-DCM Data; Secondary Endpoints Missed
Tweet Send to a Friend
Vericel Corporation (Nasdaq: VCEL) announced the presentation and publication of results from the company’s Phase 2b ixCELL-DCM clinical study of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
